1. Home
  2. NEGG vs ADCT Comparison

NEGG vs ADCT Comparison

Compare NEGG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newegg Commerce Inc.

NEGG

Newegg Commerce Inc.

HOLD

Current Price

$18.63

Market Cap

363.7M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.09

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEGG
ADCT
Founded
2001
2011
Country
United States
Switzerland
Employees
714
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
363.7M
431.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NEGG
ADCT
Price
$18.63
$1.09
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
96.6K
2.7M
Earning Date
04-28-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$8.95
$0.78
52 Week High
$137.84
$4.98

Technical Indicators

Market Signals
Indicator
NEGG
ADCT
Relative Strength Index (RSI) 37.57 15.96
Support Level $16.55 N/A
Resistance Level $21.95 $4.77
Average True Range (ATR) 2.15 0.18
MACD 0.56 -0.22
Stochastic Oscillator 38.17 10.44

Price Performance

Historical Comparison
NEGG
ADCT

About NEGG Newegg Commerce Inc.

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: